Cilostazol

CHEMBL799 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.5 g/mol

LogP

3.1

Phase

4

A phosphodiesterase 3 inhibitor that inhibits platelet aggregation and acts as a vasodilator, used to reduce symptoms of intermittent claudication in peripheral artery disease, improving walking distance. It is contraindicated in patients with heart failure of any severity because PDE3 inhibitors have been associated with increased mortality in this population. Headache and palpitations are common side effects reflecting its vasodilatory and cardiac effects.

Peso Molecular

369,5000 g/mol

LogP

3,10

TPSA

81,90 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Cardiovascular Disease Pain Management Rheumatoid Arthritis Parkinson's Disease Migraine Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Type 2 Diabetes Major Depressive Disorder Breast Cancer Chronic Pain Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1

InChI

InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

Molecular Formula

C20H27N5O2

HBD / HBA

1 / 5

Ligações Rotacionáveis

7

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A phosphodiesterase 3 inhibitor that inhibits platelet aggregation and acts as a vasodilator, used to reduce symptoms of intermittent claudication in peripheral artery disease, improving walking distance. It is contraindicated in patients with heart failure of any severity because PDE3 inhibitors have been associated with increased mortality in this population. Headache and palpitations are common side effects reflecting its vasodilatory and cardiac effects.

Yes, Cilostazol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL799. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2754. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Cilostazol no PillFYI

Estrutura

Dados Rápidos

Fórmula: C20H27N5O2

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.